| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 10/10/2001 | EP1140196A1 Soluble compositions of triphenylethylene antiestrogens |
| 10/10/2001 | EP1140195A1 Oil-in-water emulsion exhibiting a protective action against damages to human organs resulting from peroxidation, and the production and use thereof |
| 10/10/2001 | EP1140176A1 Transcutaneous photodynamic treatment of targeted cells |
| 10/10/2001 | EP1140170A1 Novel agents and methods for treatment and diagnosis of ocular disorders |
| 10/10/2001 | EP1140167A1 Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13 |
| 10/10/2001 | EP1140159A1 Oral vaccine against diarrhea |
| 10/10/2001 | EP1140150A2 Method for accelerating the rate of mucociliary clearance by using a kunitz-type serine protease inhibitor |
| 10/10/2001 | EP1140148A1 Shelf-stable formulation of glucagon-like peptide-1 |
| 10/10/2001 | EP1140145A2 Novel exendin agonist formulations and methods of administration thereof |
| 10/10/2001 | EP1140135A1 Cyclosporin solution |
| 10/10/2001 | EP1140133A1 Controlled release formulation comprising gnrh-ii |
| 10/10/2001 | EP1140121A1 Cryogranulation of activated protein c |
| 10/10/2001 | EP1140117A2 Aciclovir compositions containing dimethicone |
| 10/10/2001 | EP1140115A2 Phospholipid complexes of proanthocyanidin a2 as antiatherosclerotic agents |
| 10/10/2001 | EP1140114A2 Pharmaceutical formulations |
| 10/10/2001 | EP1140111A1 Pharmaceutical aerosol formulations containing fluoroalkanes and budesonide |
| 10/10/2001 | EP1140110A2 Clathrates of dehydroepiandrosterone and corresponding pharmaceutical compositions |
| 10/10/2001 | EP1140105A1 Controlled release galantamine composition |
| 10/10/2001 | EP1140093A2 Compositions having improved delivery of actives |
| 10/10/2001 | EP1140091A2 Formulations comprising imiquimod or other immune response modifiers for treating mucosal consitions |
| 10/10/2001 | EP1140089A1 Liposomic niflumic acid - new transdermal anti-inflammatory medicine |
| 10/10/2001 | EP1140084A1 Novel formulation |
| 10/10/2001 | EP1140081A2 Improving mental performance by increasing brain insulin sensitivity |
| 10/10/2001 | EP1140071A1 Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors |
| 10/10/2001 | EP1140068A1 Doramectin formulations |
| 10/10/2001 | EP1140061A2 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
| 10/10/2001 | EP1140059A2 Pharmaceutical aerosol formulations containing fluoroalkanes, budesonide and formoterol |
| 10/10/2001 | EP1140054A2 Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions |
| 10/10/2001 | EP1140040A1 Spray-type cosmetic composition and matrix used in said composition for dermal administration |
| 10/10/2001 | EP1140038A1 Transdermal drug delivery system |
| 10/10/2001 | EP1140037A1 Multiparticulate oral dosage forms |
| 10/10/2001 | EP1140036A2 Novel formulations comprising lipid-regulating agents |
| 10/10/2001 | EP1140035A1 Method for preparing an effervescent granulate comprising iron gluconate, granulate thus obtained and tablets containing the same |
| 10/10/2001 | EP1140034A1 Controlled release formulation of divalproex sodium |
| 10/10/2001 | EP1140033A2 Improved controlled release compositions and method |
| 10/10/2001 | EP1140030A2 Medicament forms having controlled release and containing active substances which easily dissolve in water |
| 10/10/2001 | EP1140028A1 Methods for treating ovarian cancer, poly(phosphoester) compositions, and biodegradable articles for same |
| 10/10/2001 | EP1140027A1 Dosage forms comprising porous particles |
| 10/10/2001 | EP1140026A1 Biodegradble polymer encapsulated serotonin receptor antagonist and method for preparing the same |
| 10/10/2001 | EP1140024A2 Particles for oral delivery of peptides and proteins |
| 10/10/2001 | EP1140022A2 Method of administering a compound to multi-drug resistant cells |
| 10/10/2001 | EP1140021A1 Improved formulation for topical non-invasive application in vivo |
| 10/10/2001 | EP1140020A1 Large molecule drug delivery system using aerosolized membrane-mimetic amphiphiles |
| 10/10/2001 | EP1140019A1 Aerosol formulations for buccal and pulmonary application |
| 10/10/2001 | EP1140018A1 Polyol/oil suspensions for the sustained release of proteins |
| 10/10/2001 | EP1140017A1 Water-insoluble drug delivery system |
| 10/10/2001 | EP1140016A1 Composition set and kit for use in intraocular surgery |
| 10/10/2001 | EP1140015A1 Polynucleotide compositions for intramuscular and intradermal administration |
| 10/10/2001 | EP1140013A1 Foaming antacid suspension tablets |
| 10/10/2001 | EP1140012A2 Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
| 10/10/2001 | EP1140010A2 Substrate composition and method of use for sequestration of skin irritants |
| 10/10/2001 | EP1140009A2 Absorbent article composition and method of use for sequestering skin irritants |
| 10/10/2001 | EP1140006A1 Skin protection agents containing a fragment mixture produced from hyaluronic acid by hydrolysis |
| 10/10/2001 | EP1139974A1 Soy depigmenting and skin care compositions |
| 10/10/2001 | EP1139970A2 The process for manufacturing topical ophthalmic preparations without systemic effects |
| 10/10/2001 | EP1139913A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents |
| 10/10/2001 | EP1139886A1 Methods and apparatus for enhancement of transdermal transport |
| 10/10/2001 | EP1139774A1 Improved release of medicament active agents from a chewing gum coating |
| 10/10/2001 | EP1139762A1 Hydrogen peroxide disinfectant with increased activity |
| 10/10/2001 | EP1139752A1 Methods and compositions for treatment of cell proliferative disorders |
| 10/10/2001 | EP1030657B1 Prolamin-plant polar lipid combination, preparation method and applications |
| 10/10/2001 | EP0923566A4 High molecular weight polymer-based prodrugs |
| 10/10/2001 | CN1316911A Compositions comprising sympathomimetic amine salts unsuitable for illegal use |
| 10/10/2001 | CN1316906A Stable liquid formulations of botulinum toxin |
| 10/10/2001 | CN1316898A Oral micro-emulsion composition of silybin |
| 10/10/2001 | CN1316897A Dosage form comprising liquid formulation |
| 10/10/2001 | CN1316273A Match of polyasparamide and paramagnetic metal and its preparing process and application |
| 10/10/2001 | CN1316242A High mechanical stability solid oral dosage form with slow releasing function for active composition |
| 10/10/2001 | CN1072505C Novel antibody system for biological response modifiers |
| 10/10/2001 | CN1072483C Stable, ingestabl and absorbadle NADH and NADPH therapeutic compositions |
| 10/09/2001 | US6300458 High molecular weight polymers and copolymers of BHMDO for biomedical application |
| 10/09/2001 | US6300443 Process for preparing polymeric microgels |
| 10/09/2001 | US6300362 Adding glycine hydrochloride or alanine hydrochloride or valine hydrochloride to angiotensin converting enzyme inhibitor compound for stabilization |
| 10/09/2001 | US6300361 Adding betaine hydrochloride to angiotensin converting enzyme inhibitor compound for stabilization |
| 10/09/2001 | US6300317 Eukarotic cells, polynucleotide, functional agents, membrane permeability, subcellar localization agents and polynucleotide masking agents |
| 10/09/2001 | US6300308 Methods and compositions for inducing autoimmunity in the treatment of cancers |
| 10/09/2001 | US6300089 Methods and compositions for early detection and treatment of insulin dependent diabetes mellitus |
| 10/09/2001 | US6299925 Effervescent green tea extract formulation |
| 10/09/2001 | US6299902 Absorption |
| 10/09/2001 | US6299900 Non-occlusive, percutaneous or transdermal drug delivery system |
| 10/09/2001 | US6299899 Extremely flexible plaster acting dermally or transdermally, and method for producing same |
| 10/09/2001 | US6299897 Attaching selectin binding carbohydrate to a cross-linkable lipid; attaching an acidic group to a cross linkable lipid; forming lipids into sheet; crosslinking lipids |
| 10/09/2001 | US6299888 Azelastine hydrochloride-containing percutaneous preparation having good percutaneous absorbability and reduced skin irritation |
| 10/09/2001 | US6299884 Administering antigen to animal inpresence of an immunostimulating amount of an adjuvant formulation consisting of metabolizabel oil and emulsifier for increasing immune response to antigen |
| 10/09/2001 | US6299876 Cytotoxic drug therapy |
| 10/09/2001 | CA2235025C Bone morphogenetic protein and fibroblast growth factor compositions and methods for the induction of cardiogenesis |
| 10/09/2001 | CA2203513C Liposome composition containing selegilin |
| 10/09/2001 | CA2164260C Targeting of dosages of medicines and therapeutic agents |
| 10/09/2001 | CA2142320C Sustained release tablets containing bupropion |
| 10/09/2001 | CA2095354C Method and composition for controlled delivery of biologically active agents |
| 10/09/2001 | CA2085255C Polyurethane-biopolymer composite |
| 10/09/2001 | CA1341304C Pharmaceutical composition for the prevention of sexually transmitted diseases |
| 10/07/2001 | CA2304906A1 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia |
| 10/06/2001 | CA2343259A1 A process for producing solid creatine dosage forms and dosage forms obtainable thereby |
| 10/04/2001 | WO2001073133A1 Compositions and methods for identifying and targeting cancer cells |
| 10/04/2001 | WO2001073132A1 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| 10/04/2001 | WO2001073131A1 High specificity marker detection |
| 10/04/2001 | WO2001073094A2 Novel sperm-dna complexes for genetically modifying non-human animals |
| 10/04/2001 | WO2001072958A2 Bladder cancer-specific peptides for diagnosis and therapy |
| 10/04/2001 | WO2001072846A2 Ligands directed to the non-secretory component, non-stalk region of pigr and methods of use thereof |